Skip to content

White Cell Ratios as Markers of Delirium and Outcome in Acute Ischemic Stroke.

White Cell Ratios as Markers of Delirium and Outcome in Acute Ischemic Stroke. DELirium in Acute Ischemic Stroke [DELIAS]

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03944694
Acronym
DELIAS
Enrollment
1001
Registered
2019-05-09
Start date
2015-06-30
Completion date
2019-03-31
Last updated
2019-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium, Ischemic Stroke

Keywords

delirium, stroke, neutrophil-to-lymphocyte ratio, NLR, mortality

Brief summary

The aim of this study was to investigate the role of Neutrophil-to-Lymphocyte Ratio (NLR) and other derived white cell markers as early markers of delirium and outcome after acute ischemic stroke (AIS).

Detailed description

Delirium is an acute brain disorder, potentially reversible, commonly occurring in patients with acute ischemic stroke. The pathomechanism of delirium is related to neuroinflammatory process and oxidative stress. Search for readily available diagnostic marker that will aid clinicians in early identification of delirium is an on-going process. The aim of this study was to investigate the role of Neutrophil-to-Lymphocyte Ratio (NLR) and other derived white cell markers as early markers of delirium and outcome after acute ischemic stroke (AIS).

Interventions

DIAGNOSTIC_TESTDelirium assessment.

Full blood count analysis.

Sponsors

Pomeranian Medical University Szczecin
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \>18 years) * acute ischemic stroke

Exclusion criteria

* hematology disorders * incomplete laboratory testing * no data regarding follow-up

Design outcomes

Primary

MeasureTime frameDescription
Early-onset-delirium.24 hoursDelirium within 24 hours from admission.

Secondary

MeasureTime frameDescription
Mortality at 30 days.30 daysMortality determined at follow-up on day 30 after acute ischemic stroke.
Mortality at 1 year.1 yearMortality determined at follow-up at 1 year after acute ischemic stroke.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026